Professor Margie Danchin addresses declining childhood vaccination rates and vaccine hesitancy through trust-building ...

Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD), according to a study published online July 22 in Pediatrics.

The rate of atrial fibrillation was also higher in RSV patients, although it depended on preexisting heart conditions and ...

Businesses, nonprofits, schools, assisted living facilities and other organizations now can schedule an on-site vaccine ...

This risky biotech company faces significant challenges ahead. But it has already proven its worth and may be able to do so ...

GSK plc GSK reported second-quarter 2025 core earnings of $1.23 per American depositary share (ADS), which beat the Zacks ...

Modern medicine is largely reactive—treating illness only after symptoms emerge. But a new study from the Research Institute ...

UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its ...

Drugmaker GSK said on Wednesday that Q2 revenues had grown as a strong specialty medicines performance drove sales and core ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...